ID   260F9
AC   CVCL_J908
DR   ATCC; HB-8488
DR   Wikidata; Q54583674
RX   DOI=10.3390/antib1010039;
RX   Patent=US4753894;
RX   Patent=US4938948;
RX   Patent=US4956453;
RX   Patent=US5629197;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8488.
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was conjugated to a ricin chain A to produce 260F9-rRTA which was evaluated in two phase 1 clinical trials which were not pursued due to severe toxicity of the conjugate (DOI=10.3390/antib1010039).
CC   Monoclonal antibody isotype: IgG1.
CC   Monoclonal antibody target: Human breast/ovarian cancer 55 kDa antigen.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_2199 ! Sp2/0-Ag14
CA   Hybridoma
DT   Created: 11-02-13; Last updated: 21-03-23; Version: 8
//
RX   DOI=10.3390/antib1010039;
RA   Becker N., Benhar I.;
RT   "Antibody-based immunotoxins for the treatment of cancer.";
RL   Antibodies 1:39-69(2012).
//
RX   Patent=US4753894;
RA   Frankel A.E., Ring D.B., Bjorn M.J.;
RT   "Monoclonal anti-human breast cancer antibodies.";
RL   Patent number US4753894, 28-Jun-1988.
//
RX   Patent=US4938948;
RA   Ring D.B., Frankel A.E.;
RT   "Method for imaging breast tumors using labeled monoclonal anti-human
RT   breast cancer antibodies.";
RL   Patent number US4938948, 03-Jul-1990.
//
RX   Patent=US4956453;
RA   Bjorn M.J., Frankel A.E., Laird W.J., Ring D.B., Winkelhake J.L.;
RT   "Anti-human ovarian cancer immunotoxins and methods of use thereof.";
RL   Patent number US4956453, 11-Sep-1990.
//
RX   Patent=US5629197;
RA   Ring D.B., Frankel A.E., Bjorn M.J.;
RT   "Monoclonal anti-human breast cancer antibodies.";
RL   Patent number US5629197, 13-May-1997.
//